Gavi, the Vaccine Alliance reached its target of vaccinating an estimated 86 million girls with the vaccine that prevents the human papillomavirus, or HPV — a sexually transmitted infection which can lead to cervical cancer. The organization estimates this will prevent an estimated 1.4 million deaths.
The vaccine is recommended for girls aged 9 to 14 years old — making campaigns for this vaccine unique, given that many vaccines target younger children, and so routine vaccination systems are built around that age group.
At the end of 2022, Gavi’s board approved this goal to reach 86 million girls by the end of 2025.
Printing articles to share with others is a breach of our terms and conditions and copyright policy. Please use the sharing options on the left side of the article. Devex Pro members may share up to 10 articles per month using the Pro share tool ( ).
About the author
Sara Jervingsarajerving
Sara Jerving is a Senior Reporter at Devex, where she covers global health. Her work has appeared in The New York Times, the Los Angeles Times, The Wall Street Journal, VICE News, and Bloomberg News among others. Sara holds a master's degree from Columbia University Graduate School of Journalism where she was a Lorana Sullivan fellow. She was a finalist for One World Media's Digital Media Award in 2021; a finalist for the Livingston Award for Young Journalists in 2018; and she was part of a VICE News Tonight on HBO team that received an Emmy nomination in 2018. She received the Philip Greer Memorial Award from Columbia University Graduate School of Journalism in 2014.
